Introduction
Central nervous system (CNS) primitive neuroectodermal tumors (PNET), including cerebellar PNET (medulloblastoma, PNET/MB) are the most common malignant brain tumors in children and constitute 20-25% of all pediatric brain tumors (1) . Because of the high risk of leptomeningeal dissemination, standard postoperative treatment for PNET includes not only local radiotherapy, but also craniospinal radiotherapy and chemotherapy. (2, 3) . Such treatment causes long-term morbidity including endocrine and growth disturbances, as well as neurocognitive dysfunction, which is particularly severe in young children (4) (5) (6) (7) (8) (9) .
Clinical prognostic factors for PNET have been identified over the last two decades (10) (11) (12) (13) (14) . These include metastatic stage (15) , extent of tumor resection, tumor location and age, and are currently used to distinguish a high-risk group of patients (M-stage ≥ 1, residual tumor bulk ≥ 1.5 cm 2 , age < 3 years, supratentorial tumor location) from a standard-risk group. However, investigators have appropriately avoided the use of the term "good-risk" or "good-outcome" since published survival rates in the 50-60% range do not justify this term. At the present time, clinical prognostic factors do not identify a "good-outcome" group of PNET/MB patients that can be treated with a substantially less toxic treatment strategy compared to standard treatment. As it is unlikely that new clinical prognostic factors will be found, biological prognostic factors must be identified to further improve PNET prognostic systems.
In the past decade, considerable advances have been achieved in better understanding PNET biology. Several developmentally regulated genes have been identified as markers that are independently associated with PNET outcome. Initially, increased expression of the neurotrophin-receptor TrkC was found to be associated with favorable clinical outcome (16) (17) (18) (19) (20) (21) . In this review, these biological prognostic markers of PNET are discussed in relation to attempts of establishing future risk-based stratification systems.
Neurotrophin Receptor TrkC
The development and survival of nervous system cells are regulated by various growth factors. Neurotrophins are a family of four related trophic factors which have pleiotropic effects on developing, mature and injured cells of the central and peripheral nervous system (22) (23) (24) (25) . The classic neurotrophin is the nerve growth factor (NGF), but three related neurotrophins have been cloned and sequenced including: brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT3), and neurotrophin-4/5 (NT4/5). All neurotrophins bind to the low affinity NGF receptor (LNGFR); however, it is not clear what role LNGFR plays in signal transduction. In contrast, the better understood functions of neurotrophins appear to be mediated by one or more members of a family of three high affinity neurotrophin receptor kinases, i.e. TrkA, TrkB, and TrkC. Each of the neurotrophins binds preferentially to a specific Trk receptor to initiate signal transduction. NGF binds TrkA, whereas BDNF and NT 4/5 bind TrkB, and NT-3 binds to TrkC (26) .
Neurotrophins activate Trk receptors to regulate cell proliferation, differentiation, and death in the developing and mature nervous system. PNET are composed of morphologically undifferentiated cells that resemble neuroectodermal progenitor cells of the developing CNS (27) and subsets of these tumors express neuronal and/or glial markers (2) . Studies of peripheral neuroblastomas and PNET, respectively, demonstrate that these tumors express one or more neurotrophins and neurotrophin receptors (16, 17, (28) (29) (30) . Segal et al (16) suggested in 1994 a possible association of TrkC mRNA expression and outcome in PNET/MB by performing Northern blot analysis on 12 tumor samples. Their study was 1999 expanded (17) . However, comparison of TrkC mRNA expression with clinical prognostic factors was not conducted, since the sample size was not big enough to allow multivariable analysis. We determined expression levels of TrkC mRNA in formalin-fixed paraffin-embedded primary tumor samples from 87 well characterized PNET patients utilizing in situ hybridization. Comparison of TrkC mRNA expression levels with clinical and other laboratory variables was performed using univariate and multivariable Cox regression analysis. High TrkC mRNA expression was found to be associated with higher five-year cumulative survival rate than low TrkC mRNA expression (89% vs. 46%). When compared with established clinical prognostic factors and laboratory variables of potential prognostic significance, univariate analysis showed that TrkC mRNA expression was the single most powerful predictor of outcome (hazard ratio = 4.81, P < 0.00005). In multivariable analysis, the hazard ratio remained significant (P < 0.00005) indicating that TrkC is an independent prognostic factor.
Performing immunohistochemistry and terminal UTP nick end labeling (TUNEL) on serial sections of the same archive material, we then compared TrkC mRNA expression with the expression of neuronal and glial differentiation markers, MIB-1 proliferation index and apoptotic index. PNET with high levels of TrkC mRNA were found to express more often neuronal differentiation markers (neurofilament proteins). Moreover, we found that high TrkC mRNA expression correlated significantly with higher apoptotic index (P=0.0005), but not with MIB-1 proliferation index (Personal observation)
Although the role neurotrophins may play in the induction and progression of PNET remains speculative at this moment, it is conceivable that at least some of these tumors may respond to endogenous neurotrophins. Muragaki et al (31) have reported that TrkA transfected PNET cell lines undergo differentiation and apoptosis in response to TrkA activation. Kim et al (17) reported that TrkC activation induces apoptosis in the DAOY PNET cell line. They also reported that overexpression of TrkC inhibits the growth of intracerebral DAOY xenografts and that the rate of apoptosis is significantly increased in these xenografts compared to DAOY wildtype xenografts (17) . Taken together, these studies indicate that PNET cells expressing high levels of functional TrkC may be susceptible to terminal neuronal differentiation or apoptosis through autocrine/paracrine secreted NT-3. Alternatively, functional TrkC may downregulate angiogenesis in PNET similarly to TrkA in neuroblastoma (32) . It also remains to be tested whether TrkC expression alters chemo-and/or radio-sensitivity.
ErbB2 Receptor
The type I tyrosine kinase growth factor receptor family includes four ErbB receptors: epidermal growth factor (EGF) receptor (also termed ErB/HER1), ErbB2/Neu/HER2, ErbB3/ HER3, and ErbB4/HER4. A family of ligands, the EGF-related peptide growth factors, bind the extracellular domain of ErbB receptors leading to the formation of both homo-and heterodimers. Dimerization consequently stimulates the intrinsic tyrosine kinase activity of the receptors and triggers autophosphorylation of specific tyrosine residues within the cytoplasmic domain. These phosphorylated residues serve as docking sites for Outcome predictors in PNET M A Grotzer signaling molecules involved in the regulation of intracellular signaling cascades determining the biological response to receptor activation (33, 34) . ErbB receptors are expressed in a variety of tissues of epithelial, mesenchymal, and neuronal origin, where they play fundamental roles in development, proliferation, and differentiation. Dysregulated expression of ErbB receptors, in particular ErbB2, has been implicated in the development and malignancy of numerous types of human cancers (35) (36) (37) . ErbB2 overexpression triggers ligand-independent activation of the kinase domain as a result of spontaneous dimer formation. Although ErbB2 alone may contribute to malignancy, a number of observations suggest that ErbB2 does cooperate with other ErbB receptors during tumor development. ErbB2-containing heterodimers have increased signaling potency which may result from a reduced rate of receptor ligand dissociation, and greater efficiency in mitogen activated protein kinase (MAPK) second messenger activation (38, 39) . Consequently, signaling from ErbB2 results in increased cell proliferation, colony formation in soft agar, cell migration, and invasion (33) .
Performing immunohistochemistry on 70 formalin-fixed paraffin-embedded primary PNET/ MB, Gilbertson et al (19, 40) found an overexpression of the ErbB2 and ErbB4 receptors in 86% and 66%, respectively. They demonstrated a close relationship between high tumor cell expression of the ErbB2 and ErbB4 receptors and tumor cell proliferation, metastases and poor prognosis (19, 40) . Forty-six percent of patients whose tumors had <50% ErbB2 positive tumor cells were alive at 25 years versus 17% of patients whose tumors had >50% ErbB2 immunopositivity (P = 0.0039). In addition, ErbB2 which was expressed in 86% of PNET/MB, could not be detected at any stage of cerebellar development indicating that positive deregulation of ErbB2 may contribute to PNET/MB tumorigenesis.
Considering the general importance of ErbB and ErbB2 in particular, the latter has been under intense investigation as a target for cancer therapy (41) . In this respect, a monoclonal antibody that targets the extracellular domain of ErbB2 specifically inhibits the in vitro growth of ErbB2-overexpressing tumor cells (42) . The humanized version of this antibody (Herceptin) has been validated in the clinic as an ErbB2-directed therapeutic approach and is now being used to treat metastatic breast cancer patients with tumors overexpressing ErbB2 (43, 44) . This serves as a rationale to develop similar therapeutic approaches for high-risk PNET patients whose tumors are ErbB2 positive.
Myc Oncogene
The MYC proto-oncogene, a member of a family of highly related genes, which includes MYCN and MYCL, encodes a nuclear phosphoprotein involved in the transcription of genes central to regulating cell cycle (45) , cellular proliferation (46), apoptosis (47), embryonic development, and differentiation (48) . MYC proteins form heterodimers with Max, also a helix-loop-helix leucine zipper protein. MYC/ Max heterodimers bind to specific DNA sequences located in the transcriptional control region of target genes and alter the transcription of these target genes by transactivation or transrepression.
MYC expression is normally tightly regulated throughout the cell cycle, but may become deregulated or activated contributing to malignant transformation (49). Dysregulation of MYC has been implicated in the pathogenesis of a variety of human neoplasms, including Burkitt's lymphoma (50), breast carcinoma (51), colon adenocarcinoma (52), lung carcinoma (53), and prostate carcinoma (54) . One important mechanism of MYC dysregulation results from gene amplification. Several studies show that MYC gene amplification is uncommon in PNET/MB, with an incidence of ~5% in primary tumors (20, (55) (56) (57) (58) (59) (60) . MYC gene amplification has been suggested as an indicator of poor prognosis in case reports (59, 61, 62) and in two recently published studies of 29 and 77 PNET/MB patients (55, 56) . In aggregate, however, published studies suggest that the frequency of MYC amplification is not sufficiently high to provide prognostic information of greater value than clinical variables.
In our own studies, we found that MYC mRNA expression ranges widely and does not correlate with the presence of MYC gene amplification in PNET cell lines or primary PNET/MB. This finding is consistent with that of Bruggers et al (63) who reported similar MYC mRNA expression levels in D425 cells (100-fold MYC amplified) compared to D283 cells (3-fold MYC amplified), and higher MYC mRNA expression levels in PFSK cells (single copy MYC) compared to DAOY cells (single copy MYC). Up-regulation of MYC in PNET independent from gene amplification may involve the adenomatous polyposis coli (APC) and β-catenin (CTNNB1) pathways. A subset of PNET is associated with Turcot's syndrome (64) , which is the association of colonic cancer with primary brain tumors and is characterized by germ-line mutations in the APC gene. While mutations of APC have not been detected in sporadic PNET (65) , approximately 5% of sporadic PNET have been reported to contain mutations in a second Wingless/ Wnt pathway member, β-catenin (66, 67) . Mutations in either APC or β-catenin act to stabilize β-catenin protein. Stabilized β-catenin protein accumulates and translocates into the nucleus where it complexes with Tcf4 and upregulates the transcription of MYC as well as other targets (68, 69) . In a recent Outcome predictors in PNET M A Grotzer study, aberrant nuclear β-catenin staining has been demonstrated in 18% of sporadic PNET/MB and in one PNET/MB from a Turcot's patient (67) .
Performing semiquantitative RT-PCR in 26 frozen PNET/MB samples, we found a high variability of MYC mRNA expression in primary PNET. The five-year cumulative progression-free survival rate of the group with low levels of MYC mRNA expression was 92% and significantly better than the 38% progression-free survival rate of the group with a high level of MYC mRNA expression (log rank; P = 0.0048). MYC mRNA expression levels did not correlate with metastatic stage, age, or gender of PNET patients. In multivariable analysis, correcting for these factors, the hazard ratio for MYC mRNA expression remained significant, indicating that MYC mRNA expression is of independent prognostic significance. This is consistent with the study of Herms et al (20) who determined MYC expression in 72 PNET/MB by in situ hybridization. They found that 30 patients with MYC mRNA expressing PNET/MB had a worse survival outcome than 42 patients whose tumors did not express MYC mRNA using their assay. Table 1 lists the results of research studies aimed at identifying biological prognostic markers in PNET. GFAP expression (70), Ki-67 (MIB-1) proliferation index (71) , and mitotic index (40) have been analyzed in multivariable analysis and found to have independent predictive value. However, when hazard ratios were reported, the prognostic impact of these factors was similar or less than that of clinical factors. By contrast, the predictive values of TrkC, MYC and ErbB2 expression have been shown to exceed all clinical factors (18, 21, 72) .
Other Candidates

Models Combining Biological Prognostic Factors
It is well known that the mechanisms regulating tumorigenesis are multifactorial. Therefore, it is unlikely that any single biological prognostic factor will be sufficiently robust to optimally segregate all PNET patients into risk-based strata. Accordingly, multiple factors of biological relevance are more likely to provide a more accurate system of defining risk groups. We demonstrated this by combining (73) recently extended the concept of combining biological factors by analyzing over 6800 genes in 60 primary PNET/MB using oligonucleotide microarray-based gene expression profiling. Tumors expressing genes characteristic of cerebellar differentiation or encoding extracellular matrix proteins had a favorable outcome. In contrast, poor outcome was associated with expression of genes related to cell proliferation, multidrug resistance, and ribosomal biogenesis.
Conclusion
Over the last decade, three important biological prognostic markers for PNET have been identified. They include TrkC, MYC and ErbB2. Since these molecular predictors each were developed on different patient cohorts, it is not known which will perform most accurately in future clinical studies. Moreover, these studies were based on retrospective datasets. Before molecular outcome predictors can be used to stratify patients into risk groups for clinical trials, it is necessary to validate them in prospective studies. This is the goal of ongoing clinical trials of the Children's Oncology Group (COG) in the U.S. and the International Society of Paediatric Oncology (SIOP) in Europe. Upon validation in these important prospective studies, biological prognostic factors, in addition to clinical factors, will define risk groups and help direct therapy decisions for children with PNET. In PNET/MB with favorable biological factors and no evidence of leptomeningeal tumor dissemination, therapy with reduced craniospinal radiation might retain the efficacy but reduce the toxicity and therefore improve the quality of life for the survivors.
